Genmab A/S (GMAB): Price and Financial Metrics
Genmab A/S (GMAB)
Today's Latest Price: $34.34 USD
Updated Oct 29 4:00pm
Add GMAB to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GMAB Stock Summary
- With a one year PEG ratio of 0.21, Genmab A is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.51% of US stocks.
- Of note is the ratio of Genmab A's sales and general administrative expense to its total operating expenses; merely 6.32% of US stocks have a lower such ratio.
- GMAB's price/sales ratio is 27.77; that's higher than the P/S ratio of 93.92% of US stocks.
- If you're looking for stocks that are quantitatively similar to Genmab A, a group of peers worth examining would be TLC, SPRO, HCM, AFMD, and ERYP.
- GMAB's SEC filings can be seen here. And to visit Genmab A's official web site, go to www.genmab.com.
GMAB Stock Price Chart Interactive Chart >
GMAB Price/Volume Stats
| Current price | $34.34 | 52-week high | $38.87 |
| Prev. close | $33.67 | 52-week low | $16.24 |
| Day low | $33.91 | Volume | 547,400 |
| Day high | $34.64 | Avg. volume | 667,804 |
| 50-day MA | $36.65 | Dividend yield | N/A |
| 200-day MA | $29.78 | Market Cap | 22.49B |
Genmab A/S (GMAB) Company Bio
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its portfolio includes two products, daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998 and is headquartered in Copenhagen, Denmark.
Loading social stream, please wait...